Payment overview · 2025
General Payments
$2,661.34
179 reported records · 25 companies
Healthcare provider profile · identity verified
Daniel Coulter, DO
Allopathic & Osteopathic Physicians|Family Medicine · LAPEER, MI · NPI 1942657614
Verified facts
What the public records show
CMS Open Payments records show Daniel Coulter, DO received $2,661.34 in general payments during 2025 across 179 reported records.
PFIZER INC. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Otezla, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $403.38 | 15.2% | 25 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $342.75 | 12.9% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $313.26 | 11.8% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $290.54 | 10.9% | 30 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $208.43 | 7.8% | 16 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $161.06 | 6.0% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $151.04 | 5.7% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $135.64 | 5.1% | 15 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $106.01 | 4.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.83 | 2.8% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.10 | 2.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $54.56 | 2.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.75 | 1.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.85 | 1.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.92 | 1.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $31.83 | 1.2% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $31.25 | 1.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $30.89 | 1.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.09 | 1.1% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $22.05 | 0.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.02 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.75 | 0.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.23 | 0.7% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $13.56 | 0.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.55 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,661.34 | 179 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $256.56 | 15 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $242.26 | 26 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $208.43 | 16 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $190.99 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $161.06 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $148.83 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $148.02 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $146.82 | 10 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $146.82 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $146.66 | 10 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $139.56 | 8 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $129.65 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.10 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $113.10 | 9 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $106.01 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $101.66 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $96.75 | 3 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $87.45 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $86.64 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $76.86 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $68.83 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $66.44 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $59.37 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $57.10 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $54.56 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.28 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.28 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.75 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.85 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $31.25 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.09 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| GELSYN-3 Normalized: gelsyn 3 |
Device | Bioventus LLC | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 67 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 321 | 98 |
| Lisinopril | Lisinopril | 282 | 86 |
| Losartan Potassium | Losartan Potassium | 193 | 59 |
| Prednisone | Prednisone | 168 | 118 |
| Omeprazole | Omeprazole | 165 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 41 |
| Metformin Hcl | Metformin Hcl | 114 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 112 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 30 |
| Sertraline Hcl | Sertraline Hcl | 106 | 34 |
| Famotidine | Famotidine | 105 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 31 |
| Allopurinol | Allopurinol | 97 | 29 |
| Alprazolam | Alprazolam | 94 | 19 |
| Trazodone Hcl | Trazodone Hcl | 86 | 33 |
| Gabapentin | Gabapentin | 84 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 25 |
| Ezetimibe | Ezetimibe | 76 | 20 |
| Jardiance | Empagliflozin | 76 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 25 |
| Furosemide | Furosemide | 75 | 28 |
| Ozempic | Semaglutide | 75 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 27 |
| Meloxicam | Meloxicam | 70 | 24 |
| Simvastatin | Simvastatin | 70 | 19 |
| Mounjaro | Tirzepatide | 68 | 12 |
| Eliquis | Apixaban | 67 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 31 |
| Montelukast Sodium | Montelukast Sodium | 59 | 22 |
| Tramadol Hcl | Tramadol Hcl | 58 | 14 |
| Azithromycin | Azithromycin | 55 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 15 |
| Nifedipine Er | Nifedipine | 51 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 39 |
| Naproxen | Naproxen | 41 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 26 |
| Carvedilol | Carvedilol | 39 | 12 |
| Celecoxib | Celecoxib | 38 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 12 |
| Atenolol | Atenolol | 35 | 11 |
| Pregabalin | Pregabalin | 34 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | 11 |
| Myrbetriq | Mirabegron | 32 | 11 |
| Aripiprazole | Aripiprazole | 31 | 11 |
| Potassium Chloride | Potassium Chloride | 31 | 13 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 13 |
| Fluconazole | Fluconazole | 24 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 11 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 13 |
| Finasteride | Finasteride | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Ondansetron Odt | Ondansetron | 18 | 12 |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | 11 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Colchicine | Colchicine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,661.34 · 179 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, Flexitouch Plus, GELSYN-3, GEMTESA, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, Nimbl, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, PROCLAIM, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Veozah, WAKIX, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error